Capacity of HIV1 p24 antigen screening to reduce the current residual risk of contracting HIV infection following transfusion
Fleurette F, Durieux, P
Record ID 31995000089
Given that a screening procedure to detect Human Immunodeficiency Virus (HIV) itself rather than the immune response, was made available at the beginning of 1991, ANDEM was asked to assess the value of this screening test, in addition to HIV antibody screening, in blood transfusion.
Authors' results and conclusions:
We found that few cases of HIV infection following transfusion could be prevented each year by implementing HIV1 p24 antigen screening in all French blood banks. However, the experts thought that to announce the availability of such a new test would attract people recently involved in behaviour associated with a high risk of contracting HIV, which could lead to a paradoxical increased probability of HIV contamination following transfusion.
This new screening test can therefore not be recommended. Other output or dissemination activity: The HIV1 p24 antigen test has not been implemented.
English language abstract:
An English language summary is available
- AIDS Serodiagnosis
- Blood Transfusion
- HIV Antigens
L'Agence Nationale d'Accreditation d'Evaluation en Santé
2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Agence Nationale pour le Developpement de l'Evaluation Medicale.